Metabiotics: prospects, challenges and opportunities
https://doi.org/10.33667/2078-5631-2019-2-13(388)-43-48
Abstract
In this review authors discuss modern condition of treatment and prophylaxis of human metabolic diseases associated with microecological imbalance of intestinal symbiotic microbiota. Now the most frequently for these aims various probiotic nutrient additives and functional fermented foods prepared on the basis of living bacteria have been used. Unfortunately such probiotics have not possessed the real effectiveness and are not completely safe. Instead of traditional commercially available living probiotics the authors suggest to use novel microecological means (metabiotics) that are structural components of probiotic bactrerial strains, and/or their metabolites and/or signaling molecules with known chemical structure. Metabiotics can optimize host‑specific physiological, regulator, metabolic and/or hormone/behavior functions and reactions. Metabiotics possess some advantages in future personalized medicine because they have exact chemical structure, well dosed, safe and long shelf‑life.
About the Authors
B. A. Shenderov
Moscow State University of Technology and Management n. a. K. G. Razumovsky Moscow;
Institute for Interdisciplinary Medicine
Russian Federation
Moscow
Russian Federation
Moscow
E. I. Tkachenko
Military Medical Academy n.a. S.M. Kirov of the Ministry of Defense of Russia
Russian Federation
Saint Petersburg
Russian Federation
Saint Petersburg
M. M. Zakharchenko
Kraft Co.
Russian Federation
Saint Petersburg
Russian Federation
Saint Petersburg
A. V. Sinitsa
Kraft Co.
Russian Federation
Saint Petersburg
Russian Federation
Saint Petersburg
References
1. Falony G., Joossens M., Viera-Silva S., Wang J., Darzi Y. et al. Population-level analysis of gut microbiome variation. Science. 2016; 352 (6285): 560–564.
2. Шендеров Б. А. Микробная экология человека и ее роль в поддержании здоровья. Метаморфозы. 2014; 5: 72–80.
3. Carding S., Verbeke K., Vipond D. T., Corfe B. M., Owen L. J. Dysbiosis of the gut microbiota in disease. Microb Ecol Health Dis. 2015; 26: 26191. dx.doi.org/10.3402/mehd.v26.26191.
4. Gilbert J. A., Quinn R. A., Debelius J., Morton J., Garg N. et al. Microbiome-wide association studies link dynamic microbial consortia to disease. Nature. 2016; 535: 94–103.
5. Maguire M., Maguire G. Gut dysbiosis, leaky gut, and intestinal epithelial proliferation in neurological disorders: towards the development of a new therapeutic using amino acids, prebiotics, probiotics, and postbiotics. Rev Neurosci. 2019; 30 (2): 179–201. DOI: 10.1515/revneuro-2018–0024.
6. Sonnenburg J. L., Backhed F. Diet-microbiota interactions as moderators of human metabolism. Nature. 2016; 535: 56–64.
7. Heeney DD, Gareau MG, Marco ML. Intestinal Lactobacillus in health and disease, a driver or just along for the ride? Curr Opin Biotecnol 2018; 49: 140–147. Doi:10.1016/j.cppbio.2017.08.004.
8. Venema K., do Carmo A. P. Probiotic and Prebiotics: Current Research and Future Trends. Wageningen: Caiser Academic Press. 2015: 560 p.
9. Engevik M. A., Versalovic J. Biochemical feature of beneficial microbes: foundation for therapeutic microbiology. Microbial Spectr. 2017; 5 (5). DOI: 10.1128/microbiolspec.BAD-0012–2016.
10. Hutkins R. W. 2019. Microbiology and Technology of Fermented Foods, 2nd ed.; Hoboken, N.J., Ed.; Wiley-Blackwell: Hoboken, NJ, USA.
11. Sommer M. O., Church G. M., Dantas G. The human microbiome harbors a diverse reservoir of antibiotic resistance genes. Virulence. 2010; 1: 299–303.
12. Van Reenen C. A., Dicks L. M.T. Horizontal gene transfer amongst probiotic lactic acid bacteria and other intestinal microbiota: what are the possibilities? A review. Arch Microbiol. 2011; 193: 157–68.
13. Zierer J., Jackson M. A., Kastenmuller G., Maqngino M., Long T., Telenti A. et al. The fecal metabolome as a functional readout of the gut microbiome. Nature genetics. 2018. DOI: https: doi.org/10.1038/s41588–018–0135–7.
14. Hood L. Tackling the microbiome. Science. 2012; 336 (6086): 1209. DOI: 10.1126/science.1225475.
15. Beloborodova N. V., Osipov G. A. Small molecules originating from microbes (SMOM) and their role in microbes-host relationship. MicrobEcol Health Dis. 2000; 12: 12–21.
16. Shenderov B. A. Probiotic (symbiotic) bacterial languages. Anaerobe. 2011; 17: 490–495.
17. Leeber S, Bron PA, Marco ML, Van Pijkeren J-P, Motherway M O’C et al. Identification of probiotic effector molecules: present state and future perspectives. Curr Opin Biotechnol 2018; 49: 217–223. DOI: 10.1016/j.cppbio.2017 10.007.
18. Червинец Ю. В., Червинец В. М., Шендеров Б. А. Современные представления о биотехнологическом потенциале симбиотической микробиоты человека. Верхневолжский медицинский журнал. 2018; 17 (1): 19–26.
19. Dorrestein P. C., Mazmanian S. K., Knight R. Finding the missing links among metabolites, microbes, and the host. Immunity. 2014; 40: 824–832.
20. Шендеров Б. А. Метабиотики-новая технология профилактики заболеваний, связанных с мироэкологическим дисбалансом человека. Вестник восстановительной медицины. 2017; 4: 40–49.
21. Шендеров Б. А., Ткаченко Е. И., Лазебник Л.Б, Ардатская М. Д., Синица А. В., Захарченко М. М. Метабиотики — новая технология профилактики и лечения заболеваний, связанных с микроэкологическими нарушениями в организме человека. Экспериментальная и клиническая гастроэнтерология. 2018; 151 (3): 83–92.
22. Aguilar-Toaláa J.E., Garcia-Varelab R., Garciac H. S., Mata-Harod V., González-Córdovaa A.F. et al., Postbiotics: An evolving term within the functional foods field. Trends in Food Science & Technology. 2018; 75: 105–114.
23. Shaikh A. M., Sreeja V. Metabiotics and their Health Benefits. Intl. J. Food. Ferment. 2017; 6 (1): 11–23.
24. Shenderov B. A. The microbiota as an epigenetic control mechanism. Chapter 11. In: The Human Microbiota and Chronic Disease: Dysbiosis as a Cause of Human Pathology. Eds. Luigi Nibali, Brian Henderson. 2016. London. John Willey & Sons, Inc. 179–197.
25. Singh A., Vishwakarma V., Singhal B. Metabiotics: The Functional Metabolic Signatures of Probiotics: Current State-of-Art and Future Research Priorities — Metabiotics: Probiotics Effector Molecules. Advan Biosci Biotechnol. 2018; 9: 147–189. DOI: http://www.scirp.org/journal/abb.
26. Aguilar-Toaláa J.E., Garcia-Varelab R., Garciac H. S., Mata-Harod V., González-Córdovaa A.F. et al., Postbiotics: An evolving term within the functional foods field. Trends in Food Science & Technology. 2018; 75: 105–114.
27. Sharma M., Shukla G. Metabiotics: One Step ahead of Probiotics; an Insight into Mechanisms Involved in Anticancerous Effect in Colorectal Cancer. Front. Microbiol. 2016; 7: 1940. DOI: 10.3389/fmicb.2016.01940.
28. Shenderov BA. Modern condition and prospective host microecology investigations. Microbial Ecology in Health & Diseases. 2007; 19:3, 145–149. Doi:10.1080/08910600701520933.
29. Shenderov BA. Metabiotics: novel idea or natural development of probiotic conception. Microbial Ecology in Health & Disease 2013; 24: 20399. doi.org/10.3402/mehd.v.24iO.20399.
30. Ардатская М. Д. Пробиотики, пребиотики и метабиотики в коррекции микроэкологических нарушений кишечника. Медицинский Совет, 2015; 3: 94–99.
31. Волков М. Ю., Захарченко М. М., Синица А. В., Ткаченко Е. И., Успенский Ю. П. Новые продукты функционального питания на основе биотехнологий. Военно-медицинский журнал. 2006; 5: 69–70.
32. Волков М. Ю., Ткаченко Е. И., Воробейчиков Е. В., Синица А. В. Метаболиты Bacillus subtilis как новые обещающие пробиотические препараты. Журнал микробиологии, эпидемиологии и иммунологии. 2007; 2: 75–80.
33. Минушкин О. Н., Ардацкая М. Д., Сергеев А. В., Волков М. Ю., Синица А. В. Опыт применения пробиотика «Бактистатин» в терапии хронического панкреатита. Фармация. 2006; 3: 39–43.
34. Yadav M., Verma M. K., Chauhan N. S. A review of metabolic potential of human gut microbiome in human nutrition. Arch Microbiol. 2018; 200: 203–219.
35. Rajilic-Stojanovic M., de Vos W. M. The first 1000 cultured species of the human gastrointestinal microbiota. FEMS Microbiol Rev. 2014; 38: 996–1047.
36. Шендеров Б. А. Направления развития гнотобиологии: теоретические и практические аспекты. Лечение и профилактика. 2014; 1: 80–84.
37. Ткаченко Е. И. Парадигма дисбиоза в современной гастроэнтерологии. Роль микробиоты в лечении и профилактике заболеваний в ХХI веке. Экспериментальная и клиническая гастроэнтерология. 2014; 105 (5): 4–7.
Review
For citations:
Shenderov B.A., Tkachenko E.I., Zakharchenko M.M., Sinitsa A.V. Metabiotics: prospects, challenges and opportunities. Medical alphabet. 2019;2(13):43-48. (In Russ.) https://doi.org/10.33667/2078-5631-2019-2-13(388)-43-48
Views:
2093
Email this article 